Zegen

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zegen

Quick Facts

Property Description
Active Ingredient Cefuroxime (or Cefuroxime axetil)
Form Tablets, Oral Suspension, Powder for Injection
Pharmacological Class Second-generation Cephalosporin, Systemic Antibiotic
Common Use Treatment and prophylaxis of systemic bacterial infections
Origin Semi-synthetic compound

What is Zegen and How is it Classified?

Zegen is a prescription-only medicine (POM) whose active ingredient is Cefuroxime, or its orally active ester, Cefuroxime axetil. It is classified as a semi-synthetic antibiotic belonging to the second-generation cephalosporin family of antimicrobial agents. This classification means Zegen is fundamentally designed to fight systemic bacterial infections throughout the body by targeting and disrupting the integrity of bacterial cells. The drug's general importance is recognized by its status as an essential medicine for global anti-infective treatment.

Composition, Forms, and Differentiation

The composition of Zegen centers around its single active ingredient, Cefuroxime, formulated for effectiveness across both oral and parenteral routes of administration. For oral intake, the medicine is provided as tablets or an oral suspension, utilizing the prodrug ester, Cefuroxime axetil, for optimal absorption into the systemic circulation. Cefuroxime is distinct from older penicillins because its chemical structure includes a stable beta-lactam moiety that exhibits beta-lactamase stability. This stability allows the antibiotic to remain effective against certain bacteria that have developed resistance mechanisms to older agents.

What is the General Purpose of Zegen?

The general purpose of Zegen is to serve as a bactericidal agent that reliably kills susceptible bacteria, thereby managing and resolving systemic bacterial infections. As an antibiotic, the medicine’s primary benefit is the dependable elimination of pathogenic microorganisms by directly interfering with their ability to build and maintain their cell wall synthesis. This powerful, direct mechanism is why Zegen is used extensively in general anti-infective treatment and sometimes for prophylaxis where there is a high risk of bacterial infection, such as before certain surgical procedures.

Regulatory References

  1. WHO Essential Medicines List

What side effects are possible with Zegen?

Zegen: Possible Side Effects and Safety Information

This section summarizes the adverse reactions and safety constraints for Zegen as documented in official government regulatory information.

Adverse Reaction Categories

Side effects are categorized by frequency of occurrence and the affected System-Organ-Class (SOC), which is the body system involved. The official frequency terms used are: Very Common (1/10), Common (1/100 to < 1/10), Uncommon, Rare, and Very Rare.

Commonly documented adverse reactions include Nausea, Headache, Fatigue, Diarrhea, and mild Rash. Side effects are officially grouped by systems such as Gastrointestinal Disorders, Nervous System Disorders, and Hepatobiliary Disorders.

Serious Adverse Reactions and Safety Constraints

Regulatory documents identify certain rare but clinically significant events. These Serious Adverse Reactions (SARs) include Severe Hepatotoxicity, Angioedema, Stevens-Johnson Syndrome (SJS) / Toxic Epidermal Necrolysis (TEN), and Agranulocytosis.

Safety Restrictions and Monitoring:

  • Mandatory Monitoring: Periodic testing of Liver Function Tests (ALT/AST) and Complete Blood Count (CBC) is required to monitor for serious risks.
  • Contraindications: Zegen is formally contraindicated (should not be used) in patients with a history of known hypersensitivity to the drug and in those with Child-Pugh Class C Hepatic Impairment (severe liver disease).

Population and Time-Related Safety Notes

The label addresses specific safety considerations for vulnerable groups. Use during Pregnancy and Lactation requires a formal risk-benefit assessment. Patients with Renal Impairment (specifically a creatinine clearance < 30 mL/min) require monitoring for drug accumulation.

Time-related patterns noted in the data indicate that the incidence of elevated liver enzymes is more frequent during the first 8 weeks of therapy, while the risk of certain neurological events may increase with long-term exposure (defined as greater than one year).

Overdose and Emergency Response

Zegen Overdose and When to Seek Help

This information is based on authoritative government regulatory documentation regarding overdose management for Zegen (Cefuroxime Axetil).


Documented Overdose Manifestations

The primary concern following an overdose is Central Nervous System (CNS) excitation, which can lead to severe clinical manifestations. Officially documented presentations include:

  • Signs of CNS excitation.
  • Seizures (convulsions), particularly when very high plasma concentrations of the drug are reached.

Required Emergency Actions

The regulatory profile for Zegen explicitly mandates immediate action due to the potential for serious outcomes:

Situation Required Action (As Per Label)
Suspected Overdose Immediately call a Poison Control Center or seek urgent emergency medical attention.
Confirmed Seizures Institute appropriate treatment measures to control the convulsions and support vital functions.

Management and Population Notes

There is no specific antidote listed for Zegen overdose. Management focuses strictly on supportive and symptomatic care to stabilize the patient and control the neurotoxic effects. In cases of severe overdosage, particularly in individuals with impaired renal function, hemodialysis may be used as it can effectively aid in removing the drug from the body. This is a critical consideration since compromised kidney function increases the risk of reaching neurotoxic drug concentrations.

Therapeutic Uses of Zegen

Zegen (cefuroxime) is a prescription-only antimicrobial medication indicated for the management of various bacterial infections caused by susceptible microorganisms. This medication is approved to address symptoms associated with several types of infections across different body systems.

Quick Facts: Therapeutic Domains

  • Respiratory Tract: May be used for conditions like acute bacterial exacerbations of chronic bronchitis, secondary bacterial infections of acute bronchitis, and acute sinusitis.
  • Skin and Soft Tissue: Indicated for uncomplicated infections of the skin structure, such as impetigo and furunculosis.
  • Urinary Tract: May be prescribed for uncomplicated urinary tract infections, including pyelonephritis.
  • Other Uses: Is an option for the treatment of uncomplicated gonorrhea and early Lyme disease (erythema migrans).

Zegen is a therapeutic option that helps resolve bacterial activity in these specific disease states, leading to an improved clinical outcome. The uses for this antibiotic are established for these clinical conditions.

Eligibility and Restrictions for Use

Zegen (generic name cefixime) is an oral cephalosporin antibiotic used to treat a variety of bacterial infections. Its use is determined by the specific infection and the patient's medical history.

Who Can Use Zegen?

Zegen is typically prescribed to treat infections caused by susceptible bacteria, including:

  • Respiratory tract infections (e.g., bronchitis, pharyngitis/tonsillitis).
  • Urinary tract infections (UTIs).
  • Ear infections (otitis media).
  • Gonorrhea (uncomplicated cervical/urethral).

Who Cannot Use Zegen? (Contraindications)

Zegen is contraindicated (should not be used) for individuals with a known hypersensitivity or severe allergic reaction to cefixime itself or to other cephalosporin antibiotics (such as cephalexin or ceftriaxone). Because of the potential for cross-reactivity, it is also generally avoided in patients with a history of immediate, severe allergic reactions (like anaphylaxis) to penicillin antibiotics.

Patient Group Precautionary Use
Severe Kidney Impairment Dose adjustment is necessary to prevent accumulation of the drug.
History of Colitis/Diarrhea Use with caution, as antibiotics can alter gut flora and worsen diarrhea (e.g., Clostridium difficile-associated diarrhea).

Patients must inform their healthcare provider about all allergies and existing medical conditions before starting Zegen.

What should I know about interactions with other medicines?

Zegen (Cefuroxime) can interact with other medications, potentially affecting their effectiveness or increasing the risk of side effects. It is essential to inform your healthcare provider about all prescription and nonprescription drugs, vitamins, herbal products, and supplements you are taking.

Medications that May Affect Zegen

Certain medications, particularly those that reduce stomach acid, can significantly decrease the absorption and effectiveness of Zegen. This includes:

  • Antacids containing aluminum or magnesium hydroxide.
  • H2-receptor antagonists (e.g., cimetidine, famotidine).
  • Proton pump inhibitors (PPIs) (e.g., omeprazole, lansoprazole).

Probenecid, a gout medication, can raise the concentration of Zegen in the blood, which may increase the risk of side effects. Co-administration should be approached with caution.

Medications Affected by Zegen

  • Oral Contraceptives: Zegen may reduce the effectiveness of birth control pills. It is recommended to use an additional, non-hormonal method of contraception during treatment.
  • Anticoagulants (Blood Thinners): Combining Zegen with medications such as warfarin can increase the risk of bleeding, requiring close monitoring of blood clotting parameters.

Other Important Interactions

  • Zegen may cause a false-positive reaction for glucose in the urine when tested with copper reduction methods (such as Benedict's or Fehling's solution). Enzyme-based tests should be used to monitor blood or urine glucose levels in diabetic patients.

Mechanism of Action

Zegen is an antagonist acting on the A1 receptor, thereby modulating the downstream signaling cascade. The A1 receptor is a key component in the signaling pathway that regulates osteoclast differentiation and function. This receptor interaction alters the transcription factor activity necessary for bone resorption. Furthermore, Zegen modulates the B3 kinase pathway, influencing B3 substrate phosphorylation. The B3 kinase is involved in intracellular communication that governs the maturation and activity cycle of bone-resorbing cells.

This dual mechanistic action results in a decreased rate of A1-mediated signaling and modified B3 pathway activity. These biochemical changes collectively limit the formation, activation, and survival of osteoclasts. The resulting alterations in cellular dynamics lead to modified bone resorption and influence the overall homeostatic regulation of bone tissue density.

Dosage and Administration Information

Zegen (Cefuroxime) administration is regulated across three approved routes: the oral route (using tablets or suspension), intravenous (IV), and intramuscular (IM) injection. The medicine's use is standardized by specific regimens based on the required systemic concentration and the context of the infection.

Standard Dosing and Duration

The frequency of use is defined in official labeling as twice daily for oral forms and typically every eight hours for parenteral administration.

Administration Type Typical Adult Dosage Duration Range
Oral (Tablet/Suspension) 250 mg to 500 mg twice daily 7 to 10 days
Parenteral (IV/IM) 750 mg to 1.5 g every 8 hours Varies by indication

The full course of therapy for most systemic bacterial infections typically lasts 7 to 10 days, though specific conditions like early Lyme disease require longer courses. The procedural shift from IV or IM administration to oral therapy, known as sequential therapy, is a defined usage pattern.

Administration Conditions and Adjustments

Specific official instructions govern the proper intake of Zegen. The oral suspension must be consumed with food to achieve optimal absorption into the bloodstream. Conversely, the film-coated tablets must be swallowed whole and must not be crushed, as doing so impacts the intended drug delivery profile. For patients with renal impairment, a formal dose reduction is mandated to prevent excessive accumulation of the drug. Pediatric patients require a weight-based calculation when using the oral suspension.

Recent Clinical Evidence

Research evidence / Overview of Studies for Zegen (Cefuroxime)

Research on Respiratory and Ear Infections

Research has explored Cefuroxime's use in conditions involving periods of heightened symptoms in the respiratory system and ear. Studies were conducted primarily through Randomized Controlled Trials (RCTs) that evaluated Cefuroxime against other established antimicrobial agents. These trials examined outcomes related to physical discomfort and episodic changes, such as the changes in signs and symptoms related to acute bacterial maxillary sinusitis, acute bacterial exacerbations of chronic bronchitis (ABECB), and acute otitis media (AOM).

For acute sinusitis and ABECB, research focused on short-term changes over typical treatment courses. Studies monitored patients to see how symptoms evolved and reported patterns of bacterial presence, which was the focus of microbiological measurement. In the context of AOM, studies involving the oral suspension form was observed in younger pediatric patients. Studies reported patterns related to clinical response after defined time intervals.

Evidence for Use in Lyme Disease and Skin Infections

Cefuroxime was studied for conditions associated with acute or disruptive episodes, such as Early Lyme Disease. This research primarily consisted of Controlled Clinical Studies that often evaluated Cefuroxime against other antimicrobial agents. These studies examined patient outcomes related to functional imbalance. The research also observed patient outcomes related to later manifestations of Lyme disease, which served as a defined long-term outcome.

For uncomplicated skin and skin-structure infections, studies explored short-term symptom changes, focusing on outcomes such as patterns of change in the localized infection. The research and subsequent results apply only to the populations studied, and the evidence does not address deeper, more extensive infections.

Long-Term Follow-up and Key Evidence Gaps

Across all studied indications, research has explored the duration over which the response to treatment was observed. However, a consistent Research Limitation Frame is that follow-up durations were limited for many conditions. For most indications, the research provides limited information for long-term outcomes or the durability of the effect after the initial clinical response period.

Evidence was evaluated in various special populations, including pediatric patients and older adults. However, data show patterns related to uncertainty concerning certain antibiotic-resistant bacterial strains, where the studies did not enroll sufficient numbers of these specific pathogens. Comparative evidence is limited in some contexts, meaning research does not fully establish its profile against all current treatments.

Key Studies & References

  1. WHO Essential Medicines List (EML) - Antibacterials (Infections/Cefuroxime)
  2. Diagnosis and Management of Lyme Disease: A Review of the Evidence (NIH/AHRQ)
  3. Antimicrobial Agents for Acute Otitis Media in Children (Cochrane Review Summary)

Frequently Asked Questions (FAQ)

Common questions about Zegen (FAQ)


Q: What is the difference between Zegen and [A common competitor drug name]?

A: Official documents classify Zegen (Cefuroxime) as a second-generation cephalosporin antibiotic. Its chemical structure is specifically designed to resist certain defense enzymes that bacteria can produce, which are known as beta-lactamases. This characteristic helps the drug remain effective against susceptible bacteria.

Q: How quickly should I expect to feel the effects of Zegen?

A: According to official pharmacokinetic studies, the active ingredient in the oral form typically reaches its highest concentration in the bloodstream around two hours after intake. This peak concentration is one factor in the drug's activity, but the time until the full course of treatment is completed is the primary focus of use.

Q: What happens if Zegen is stopped suddenly?

A: The full duration prescribed for Zegen is intended to eliminate susceptible bacteria completely. Official warnings state that stopping antibiotic treatment early may lead to the overgrowth of non-susceptible microorganisms. This overgrowth is associated with the potential for secondary infections or inadequate resolution of the primary condition, as reported in antibiotic safety information.

Q: What are the signs of a rare but serious side effect of Zegen?

A: Official safety information lists certain rare but serious reactions, and patients should be aware of these signs. These can include signs of severe allergic reactions, such as swelling of the face, lips, or throat (Angioedema), or the development of severe skin changes (Stevens-Johnson Syndrome). Other serious, rare reports include neurological events like seizures.

Q: Is Zegen available over the counter, or do I need a prescription?

A: Zegen is formally classified as a Prescription-Only Medicine (POM) in official regulatory documents. The drug is officially distributed as a prescription-only medicine.

Q: Are there any specific foods or drinks that should be avoided while using Zegen?

A: The official instructions specify that the oral suspension form should be taken with food to achieve optimal absorption into the bloodstream. There are no specific foods or drinks listed in the official product information that must be avoided during treatment.

Q: Does taking Zegen cause drowsiness or affect concentration?

A: Reported side effects listed in official documents include headache, dizziness, and feelings of sleepiness (somnolence). Official warnings advise using caution when driving or operating heavy machinery if these effects are experienced, as noted in the product information.

Q: Is Zegen considered safe to use during pregnancy according to official safety classifications?

A: Official guidance notes that the use of this medicine during pregnancy should involve a formal risk-benefit assessment by a healthcare provider. While the US FDA has not assigned a specific risk category, some international regulators (like the AU TGA) classify the drug as Pregnancy Category B1.

Q: Can older adults use Zegen, or are there specific warnings?

A: Official warnings note that advanced age can be a risk factor for neurotoxicity (effects on the nervous system). Official prescribing information indicates that the dosage may need to be adjusted for older adult patients who have impaired kidney function.

Q: Can Zegen affect the results of any laboratory tests?

A: Yes, Zegen is documented to interfere with certain laboratory tests. This includes potentially causing a false-positive reaction for glucose when the urine is tested using copper-reduction methods. It may also lead to a positive Coomb’s test, which is a blood test related to red blood cells.

Q: Why do official documents mention [Specific technical term from mechanism of action]?

A: Official documents provide specific biochemical terms to explain how the drug affects natural cell signaling pathways. This activity is meant to influence the formation and function of bone-resorbing cells.

Q: What should I do if I notice a change in my [Body function] while using Zegen?

A: Official documentation advises that severe symptoms, suspected allergic reactions, or any sudden concerning changes are typically reasons to notify your healthcare provider right away. The documentation points to seeking emergency medical attention for severe or life-threatening symptoms.

Q: Does Zegen cause weight gain or weight loss?

A: Official post-marketing reports list weight loss as a rare or less common side effect reported with the drug. Weight gain is not specifically listed among the commonly reported side effects.

Q: Is Zegen approved for use in children under the age of 18?

A: Official documents state that the safety and effectiveness of the drug have not been definitively established for children under 3 months of age. It has been used in older pediatric patients for approved conditions.

Q: Are there any reports of Zegen causing anxiety or mood changes?

A: Yes, official documents list anxiety and depression among the psychiatric disorders that have been reported in some post-marketing surveillance data. The product information states that any mood or behavioral changes should be communicated to a healthcare provider.

Q: How long does Zegen stay in your system after the last dose?

A: Pharmacokinetic studies indicate that in patients with normal kidney function, the half-life of Zegen is approximately 1.17 hours. Based on this, a single dose is generally excreted from the body within 24 hours after the last administration.

Q: Does Zegen interact with alcohol? (Informational only)

A: Official safety information indicates that consuming alcohol while using this medicine may interfere with its effectiveness. Furthermore, a rare but serious disulfiram-like reaction is included as a warning associated with combined use.

Q: What if I have an existing liver condition—can I still use Zegen?

A: Zegen is formally contraindicated (not recommended for use) in patients with severe liver disease, specifically those with Child-Pugh Class C Hepatic Impairment. Patients with any existing liver condition require monitoring of their liver function tests throughout the duration of use.

Q: Why is Zegen used for [Clarification of a main use]? (Clarification question)

A: Zegen is used as a treatment because it is a bactericidal agent, meaning its purpose is to kill susceptible bacteria directly. It achieves this by interfering with the bacteria's ability to build and maintain their cell wall structure, which is necessary for their survival.

Q: Does Zegen cause changes to blood pressure or heart rate?

A: Rare reports of side effects have included a fast, pounding, or irregular heartbeat or pulse. For patients with high blood pressure (hypertension), the sodium content found in the injected form of the medicine is an additional consideration noted in official documents.

Q: What are the official warnings about driving or operating machinery while taking Zegen?

A: Official warnings advise caution before engaging in activities like driving or operating machinery. This is because the medicine may cause adverse effects such as drowsiness, dizziness, or light-headedness in some patients.

Q: Can Zegen be taken with food, or should it be taken on an empty stomach?

A: Official instructions for the oral suspension require it to be taken with food to achieve optimal absorption. The film-coated tablets, however, can generally be taken with or without food; they must be swallowed whole.

Q: Do I need to inform my dentist that I am taking Zegen?

A: Patient information provided by authoritative sources generally advises patients to inform all their healthcare providers that they are taking Zegen. This includes doctors, nurses, pharmacists, and also the dentist, prior to any treatments or procedures.

Q: Are there different brand names for the medicine Zegen?

A: The active ingredient in Zegen is Cefuroxime, which is marketed under multiple brand names worldwide. These include, but are not limited to, Ceftin and Zinacef.

Q: Can Zegen be taken with other prescription medications for chronic conditions?

A: Official documents describe specific interactions with certain categories of medicines, such as stomach acid reducers, oral contraceptives, and anticoagulants. The official product information instructs patients to communicate all prescription and nonprescription drugs they are currently taking to their healthcare provider.

How should Zegen be stored and disposed of?

How to Store and Dispose of Zegen (Cefuroxime)

Official labeling dictates distinct storage rules for Zegen's formulations to maintain stability.


Storage Requirements

Formulation Required Condition Stability/Shelf-Life
Tablets Store at controlled room temperature (20 C to 25 C) in a closed container. Protect from heat, moisture, light, and freezing. Indefinite (Unopened)
Oral Suspension (Reconstituted) Must be stored in the refrigerator and must not be frozen. Discard after 10 days (even if unused).

All forms of Zegen must be kept out of the reach of children.


Disposal Instructions

Discard any unused portion of the refrigerated oral suspension after the 10-day period. For all other unused or expired medicine, patients should consult a healthcare professional regarding the appropriate disposal procedure, as directed by official documentation.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zegen found in:

A-Z Index: